EP0447727A1 — Novel 8-sulfamylmethylene-2-amino tetralins
Assigned to Aventis Pharmaceuticals Inc · Expires 1991-09-25 · 35y expired
What this patent protects
A compound of the formula the enantiomeric forms thereof and pharmaceutically acceptable salts thereof wherein R₁ and R₂ each represents hydrogen or methyl, and R₃ is C₁₋₇ lower alkyl, for use as pharmaceutically active compound.
USPTO Abstract
A compound of the formula the enantiomeric forms thereof and pharmaceutically acceptable salts thereof wherein R₁ and R₂ each represents hydrogen or methyl, and R₃ is C₁₋₇ lower alkyl, for use as pharmaceutically active compound.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.